Sunesis Pharmaceuticals – Consensus Indicates Potential 77.6% Upside

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

Sunesis Pharmaceuticals with ticker code (SNSS) now have 2 analysts in total covering the stock. The consensus rating is ‘Hold’. The range between the high target price and low target price is between 5 and 1.5 calculating the mean target price we have 3.25. With the stocks previous close at 1.83 this would imply there is a potential upside of 77.6%. There is a 50 day moving average of 1.53 and the 200 day moving average is 2.3. The company has a market capitalisation of $33m. You can visit the company’s website by visiting: http://www.sunesis.com

The potential market cap would be $59m based on the market concensus.

Sunesis Pharmaceuticals, a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of hematologic and solid cancers. Its lead product candidate is vecabrutinib, a non-covalent inhibitor of Bruton’s tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and other B-cell malignancies. The company is also developing SNS-510, which is in preclinical pharmacology studies for the treatment of solid tumor and hematologic malignancies; various other partnered programs, such as TAK-580, a pan-Raf inhibitor program that is in Phase 1 clinical trial for the treatment of pediatric low-grade glioma; and vosaroxin, an anti-cancer quinolone derivative that intercalates DNA and inhibits topoisomerase II. It has a collaboration agreement with Biogen Idec MA to discover, develop, and commercialize small molecule BTK inhibitors; and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize preclinical inhibitors of PDK1. Sunesis Pharmaceuticals was founded in 1998 and is headquartered in South San Francisco, California.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:

      Search

      Search